Oral folic acid versus placebo in the treatment of males with the fragile X syndrome

Randi J Hagerman, A. W. Jackson, A. Levitas, M. Braden, P. McBogg, M. Kemper, L. McGavran, R. Berry, I. Matus

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

A double-blind, crossover study of a 10 mg folic acid per day (vs. placebo) treatment was carried out in 25 fra(X) males (ages 1-31 years). Each treatment period lasted 6 months. Before, during and after the study, the patients were assessed blindly with psychological, language and behavioral evaluations, and parent or caretaker reports were collected. Standardized testing did not show statistically significant changes in the group as a whole; psychological testing demonstrated a statistically significant improvement on folic acid in the prepubertal males. After uncoding, caretaker or parent reports also demonstrated behavioral improvements in the prepubertal males while being treated with folic acid.

Original languageEnglish (US)
Pages (from-to)241-262
Number of pages22
JournalAmerican Journal of Medical Genetics
Volume23
Issue number1-2
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Oral folic acid versus placebo in the treatment of males with the fragile X syndrome'. Together they form a unique fingerprint.

  • Cite this

    Hagerman, R. J., Jackson, A. W., Levitas, A., Braden, M., McBogg, P., Kemper, M., McGavran, L., Berry, R., & Matus, I. (1986). Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. American Journal of Medical Genetics, 23(1-2), 241-262.